Harlan Krumholz/LinkedIn
Dec 11, 2025, 12:50
Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
Harlan Krumholz, Harold H. Hines Jr. Professor at Yale University, shared on LinkedIn:
”Clinical trials rarely come with expiration dates.
Yet the patients we treat today are not the same as those studied 40 years ago.
New trials on beta blockers after myocardial infarction highlight how much cardiology has changed, and how slowly our evidence adapts.
This is not simply about one therapy.
It is about the half-life of evidence and the need for modern, pragmatic, real-time trials that keep pace with evolving practice.
I explored this in my latest piece.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH
-
Sep 25, 2026, 05:24Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment
-
Sep 25, 2026, 05:15Maria Cherska: High Cholesterol Isn’t Always Diet or Lifestyle – Sometimes It’s Genetic
-
Sep 25, 2026, 05:07Nancy Braithwaite: BBTS Specialist Certificate in Transfusion Science Practice
-
Sep 24, 2026, 18:43Hugh Nguyen: Honored to Accept the Friend of Singapore Red Cross Award
-
Sep 24, 2026, 18:42Titilope Fasipe: Proud to Support American Society of Hematology’s SCD Initiative